Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A 2nd Open-Label Extension for 5 Years to: The Placebo-Controlled 1st Extension to a Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Odanacatib (MK-0822) to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D and Calcium
Objectives 1st extension: 1. To assess the effect of treatment up to 5 years with odanacatib on the risk of morphometrically assessed vertebral fractures compared to placebo. 2. To assess safet...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Study of safety and efficacy of different doses of the study drug, MK-0854/Losartan Potassium, in pediatric patients with high blood pressure assigned to different groups randomly. Treatment is known to doctor and patient
(1) To define a dose-response relationship for losartan in hypertensive children aged 6 months to 6 years, after a 21-day open-label treatment period (response assessed by change from baseline in mean...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Pembrolizumab in Subjects with Advanced Recurrent Ovarian Cancer
(1) To evaluate clinical anti-tumor activity of pembrolizumab monotherapy based on overall response rate (ORR) as assessed by CIV per RECIST 1.1 in Cohort A-All Comer group (2) To evaluate clinical...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A 24-Month Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Postmenopausal Women with Osteoporosis
For Base Study: To assess the effect of L-001037536 3 mg weekly, 10 mg weekly, 25 mg weekly, and 50 mg weekly on lumbar spine BMD compared to placebo over 12 months. For 24 Months Extension: To ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
A Study of the Efficacy and Safety of MK-4618 in Patients with Overactive Bladder (OAB)
1. To assess the long-term safety and tolerability of treatment with MK-4618 compared to tolterodine ER. 2. To assess the long-term safety profile of MK-4618 dosed concomitantly with tolterodine ER...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate AD (EPOCH)
Part I (main cohort) - Primary Trial Objectives: 1. To assess the efficacy of two doses of MK-8931 on cognition in subjects with mild to moderate AD. 2. To assess the efficacy of two doses of MK-893...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE ESTUDIO PARA EVALUAR LOS SUCESOS CARDIOVASCULARES TRAS EL TRATAMIENTO CON ERTUGLIFLOZINA EN PACIENTES CON DIABETES MELLITUS TIPO 2 Y ENFERMEDAD CARDIOVASCULAR ESTABILIZADA
Objective: To demonstrate the non inferiority of ertugliflozin compared with a non ertugliflozin comparator group on the time to first occurrence of any of the components of the composite endpoint of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Randomized Sitagliptin Withdrawal Study
In subjects with T2DM with inadequate glycemic control on metformin and sitagliptin, who initiate and titrate insulin glargine (LANTUS®), to assess the effect of continuing sitagliptin relative to wit...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
OS Study of Pembrolizumab (MK-3475) vs. SOC in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic NSCLC (Keynote 042)
1) To compare the overall survival (OS) in subjects with PD-L1 strongly positive, 1L advanced/metastatic NSCLC treated with pembrolizumab compared to standard of care (SOC) chemotherapies. 2) To co...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 5 ans
Adult Lamivudine and Tenofovir Biocomparison Study for Pediatric Fixed Dose Combination Formulation
To evaluate the comparative bioavailability of: 1.lamivudine 300mg: a. adult marketed tablets to the investigational oral pediatric uncoated/coated granules-fasted conditions b.investigational oral...
Country
None
organs
None
Specialty
None
More information
Previous
6
7
8
9
10
11
12
13
14
15
Next